image
Healthcare - Medical - Devices - NASDAQ - US
$ 100.17
-0.169 %
$ 3.15 B
Market Cap
-27.6
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRTC stock under the worst case scenario is HIDDEN Compared to the current market price of 100 USD, iRhythm Technologies, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRTC stock under the base case scenario is HIDDEN Compared to the current market price of 100 USD, iRhythm Technologies, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRTC stock under the best case scenario is HIDDEN Compared to the current market price of 100 USD, iRhythm Technologies, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IRTC

image
$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
592 M REVENUE
20.13%
-116 M OPERATING INCOME
7.71%
-113 M NET INCOME
100.00%
3.39 M OPERATING CASH FLOW
106.77%
-123 M INVESTING CASH FLOW
-10072.29%
511 M FINANCING CASH FLOW
5697.97%
164 M REVENUE
11.38%
-4.08 M OPERATING INCOME
91.88%
-1.33 M NET INCOME
97.11%
19.2 M OPERATING CASH FLOW
-21.01%
-122 M INVESTING CASH FLOW
-120.77%
2.99 M FINANCING CASH FLOW
8634.29%
Balance Sheet iRhythm Technologies, Inc.
image
Current Assets 646 M
Cash & Short-Term Investments 536 M
Receivables 79.9 M
Other Current Assets 30.3 M
Non-Current Assets 286 M
Long-Term Investments 61.9 M
PP&E 173 M
Other Non-Current Assets 51.1 M
57.50 %8.58 %3.26 %6.65 %18.54 %5.48 %Total Assets$931.4m
Current Liabilities 111 M
Accounts Payable 7.22 M
Short-Term Debt 15.9 M
Other Current Liabilities 87.8 M
Non-Current Liabilities 730 M
Long-Term Debt 721 M
Other Non-Current Liabilities 8.58 M
10.45 %85.78 %Total Liabilities$840.5m
EFFICIENCY
Earnings Waterfall iRhythm Technologies, Inc.
image
Revenue 592 M
Cost Of Revenue 184 M
Gross Profit 408 M
Operating Expenses 523 M
Operating Income -116 M
Other Expenses -2.22 M
Net Income -113 M
600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)592m(184m)408m(523m)(116m)2m(113m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.86% GROSS MARGIN
68.86%
-19.52% OPERATING MARGIN
-19.52%
-19.14% NET MARGIN
-19.14%
-124.62% ROE
-124.62%
-12.16% ROA
-12.16%
-13.88% ROIC
-13.88%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis iRhythm Technologies, Inc.
image
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -113 M
Depreciation & Amortization 25.8 M
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 0
Others 3.39 M
Free Cash Flow 3.39 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets iRhythm Technologies, Inc.
image
Wall Street analysts predict an average 1-year price target for IRTC of $115 , with forecasts ranging from a low of $78 to a high of $145 .
IRTC Lowest Price Target Wall Street Target
78 USD -22.13%
IRTC Average Price Target Wall Street Target
115 USD 14.73%
IRTC Highest Price Target Wall Street Target
145 USD 44.75%
Price
Max Price Target
Min Price Target
Average Price Target
15015014014013013012012011011010010090908080707060605050May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership iRhythm Technologies, Inc.
image
Sold
0-3 MONTHS
10.1 M USD 8
3-6 MONTHS
1.46 M USD 2
6-9 MONTHS
373 K USD 3
9-12 MONTHS
294 K USD 3
Bought
0 USD 0
0-3 MONTHS
501 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
21 K USD 1
9-12 MONTHS
7. News
iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago, IL. Drawing on data from more than 1.1 million patients who used iRhythm's Zio® long-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (24–48-hour) monitoring, such as with Holter devices, fails to detect a significant proportion of actionable arrhythmias—even in patients reporting “daily symptoms”—and that Symptom–Rhythm Correlation (SRC) is notably low for most arrhythmias, underscoring that selection of monitoring duration based on the frequency of symptoms alone can lead to undetected (missed) actionable1 arrhythmias. globenewswire.com - 1 week ago
iRhythm Technologies (IRTC) Upgraded to Buy: Here's What You Should Know iRhythm Technologies (IRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 weeks ago
iRhythm Technologies, Inc. (IRTC) Q4 2024 Earnings Call Transcript iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, IR Quentin Blackford - President & CEO Daniel Wilson - CFO Conference Call Participants Macauley Kilbane - William Blair Lilia-Celine Lozada - JPMorgan Kallum Titchmarsh - Morgan Stanley Nathan Treybeck - Wells Fargo David Roman - Goldman Sachs Sam Eiber - BTIG Jon Young - Canaccord Genuity David Rescott - Baird Suraj Kalia - Oppenheimer Felipe Lamar - Truist Paige Chamberlain - Wolfe Research Operator Good afternoon. Thank you for attending today's iRhythm Technologies Q4 2024 Earnings Conference Call. seekingalpha.com - 1 month ago
IRhythm Technologies (IRTC) Beats Q4 Earnings and Revenue Estimates IRhythm Technologies (IRTC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.30 per share. This compares to loss of $1.26 per share a year ago. zacks.com - 1 month ago
iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024. globenewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Connect NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 1 month ago
Will iRhythm Technologies (IRTC) Report Negative Earnings Next Week? What You Should Know IRhythm Technologies (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Reach Out NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Shareholders to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 1 month ago
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 2 months ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 2 months ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 2 months ago
8. Profile Summary

iRhythm Technologies, Inc. IRTC

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 3.15 B
Dividend Yield 0.00%
Description iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Contact 699 8th Street, San Francisco, CA, 94103 https://www.irhythmtech.com
IPO Date Oct. 20, 2016
Employees 2000
Officers Dr. Minang P. Turakhia M.D., M.S. Chief Medical & Scientific Officer and Executive Vice President of Product Innovation Mr. Daniel G. Wilson Chief Financial Officer, Principal Financial Officer, EVice President of Corporate Development & Investor Relations Mr. Chad M. Patterson Chief Commercial Officer Mr. Mervin Smith Executive Vice President of Business Operations Ms. Stephanie Zhadkevich Director of Investor Relations Ms. Sumi Shrishrimal Executive Vice President & Chief Risk Officer Mr. Patrick Michael Murphy J.D. Chief Business & Legal Officer Mr. Marc Rosenbaum Senior Vice President of Finance & Chief Accounting Officer Mr. Quentin S. Blackford President, Chief Executive Officer & Director